National Institutes of Health, Public Health Service, DHHS.
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.
A3 Adenosine Receptor Agonists
Kenneth A. Jacobson et al. (NIDDK).
U.S. Provisional Patent Application No. 60/608,823 filed 09 Sep 2004 (DHHS Reference No. E-248-2004/0-US-01).
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426; firstname.lastname@example.org.
Researchers have been pursuing compounds that activate or inhibit adenosine A3 receptors because these cell membrane proteins have a wide range of physiological and disease-related effects and are thus considered to be promising drug targets. The adenosine A3 receptors are G-protein-coupled receptors and are found mostly in brain, lung, liver, heart, kidney, and testis. When this receptor is activated moderately, a cytoprotective effect is observed, such as reducing damage to heart cells from lack of oxygen. However, at high levels of stimulation they can cause cell death. Both agonists and antagonists are being tested for therapeutic potential, for example, treatment of cancer, heart conditions, neurological conditions, pain, asthma, inflammation and other immune implications.
Adenosine receptors have provided fertile leads for pharmaceutical development, and there are currently a variety of adenosinergic compounds advancing toward clinical trials. Therapeutics which target the adenosine A3 receptors is now an emerging focus that the major pharmaceutical companies are developing. Smaller companies are also developing drugs that stem from proprietary technology targeting adenosine A3 receptors. These companies have products in clinical trials for colorectal cancer and rheumatoid arthritis.
This invention pertains to highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides.
This research has been published, in part, in S. Tchilibon, B.V. Joshi, S.-K. Kim, H.T. Duong, Z.-G. Gao, and K.A. Jacobson, “N-methano adenosine derivatives as A3 receptor agonists,” J. Med. Chem., ASAP web release date 23 Sep 2004, doi: 10.1021/jm049580r.
In addition to licensing, the technology is available for further development through collaborative research with the inventors via a Cooperative Research and Development Agreement (CRADA).
Apparatus for Multifocal Deposition and Analysis
Bradford Wood, Alexander Gorbach, Ziv Neeman, Julia Hvisda (all of NIHCC), et al. U.S. Provisional Patent Application No. 60/403,875 filed 16 Aug 2002 (DHHS Reference No. E-248-2001/0-US-01); International Application Number PCT/US03/25575 filed 14 Aug 2003, which Start Printed Page 6705published as WO 2004/016155 A3 on 26 Feb 2004 (DHHS Reference No. E-248-2001/0-PCT-02).
Licensing Contact: Michael Shmilovich; (301) 435-5019; email@example.com.
Available for licensing and commercial development is a multifocal apparatus for delivering an agent or for gathering information about a biological tissue, such as optical spectroscopy for tissue characterization (nuclear chromatic density). The apparatus includes a needle or catheter having a lumen extending longitudinally at least partially through it and a deployment port within the distal portion of the catheter. A plurality of extendable-retractable needles are housed within the catheter lumen, when deployed, extend through the deployment port. The needles may be solid or hollow and may deliver an agent to the tissue, include a mechanism for gathering information about the tissue, or both. Optical spectroscopy in a needle-based system provides in vivo tissue characterization without removal of tissue for microscopic analysis, which may be helpful during surgery or image guided therapies to localize cancerous tissue.
Figure 1 is a schematic diagram of one embodiment of the apparatus in use. The distal end of the apparatus is shown within a neoplasm and the needles are in a deployed state.
Figure 2 is an enlarged, longitudinal section through the distal end of an embodiment of the apparatus, showing several extendable-retractable needles in a non-deployed, or retracted, state.
In addition to licensing, the technology is available for further development through collaborative research with the inventors via a Cooperative Research and Development Agreement (CRADA).Start Signature
Dated: February 1, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.
[FR Doc. 05-2365 Filed 2-7-05; 8:45 am]
BILLING CODE 4140-01-P